Endonovo Therapeutics Inc. (ENDV) Appoints National Leader in Pain Management to Scientific Advisory Board

July 3, 2019 11:43:06
  • Appointment of Dr. Steven Levin of Johns Hopkins University to Endonovo’s scientific advisory board is expected to help facilitate the introduction of Endonovo’s non-invasive bio-electrical medical devices to hospitals and clinics
  • The global wearable medical devices market is expected to grow to nearly $67 billion by 2026 at a CAGR of 26.1 percent
  • Endonovo holds 27 patents and numerous trademarks for several proprietary technologies and medical devices

Endonovo Therapeutics Inc. (OTCQB: ENDV), a commercial-stage developer of non-invasive electroceutical therapeutic devices, has appointed Dr. Steven Levin, M.D., a national leader in the field of pain management, to its scientific advisory board. Levin is the regional medical director at Johns Hopkins School of Medicine and medical director at Howard County General Hospital in Columbia, Maryland. He is also an assistant professor at Johns Hopkins School of Medicine’s Department of Anesthesiology.

“Dr. Levin’s vast experience with novel therapies in the anesthesiology and pain management field, as well as his strong research interest to improve clinical practice in pain management, will be valuable scientific additions to Endonovo,” Alan Collier, CEO of Endonovo Therapeutics, said in a news release (http://nnw.fm/PeF8s). “As a leader in the field of pain management, Steven will contribute valuable knowledge and expertise as we move our programs forward.”

Levin’s membership in professional and scientific societies has included the American Society of Anesthesiology, the American Pain Society, the American Society of Regional Anesthesia, the Society in Anesthesia and the International Association for the Study of Pain. He is currently the co-chair of the Opioid Stewardship Clinical Community, as well as a clinical design team leader of the Musculoskeletal Center in the Johns Hopkins Health System.

“It is a great opportunity to participate in developing Endonovo’s promising fight to support pain management and healing in a natural and holistic way,” Levin stated in the release. “I look forward to helping guide Endonovo’s breakthrough treatments and fight against the opioid crisis as a member of the scientific advisory board.”

Levin will work with Endonovo to facilitate the introduction of SofPulse to health care facilities and further develop the company’s electroceutical devices pipeline. Endonovo has entered an agreement to distribute SofPulse to Veterans Administration facilities and Department of Defense health care facilities (http://nnw.fm/Z0zAx), and the company recently announced its national rollout plan to be in hospitals throughout the nation by 2020 (http://nnw.fm/BH6yN).

SofPulse Electroceutical Therapy is a non-invasive device that delivers pulsed electromagnetic frequencies to enhance post-surgical recovery (http://nnw.fm/BaoM5). SofPulse naturally speeds the healing process, significantly reduces pain and edema (swelling), reduces the need for addictive opioids and narcotics, and improves the patient recovery experience. Cleared by the FDA for treatment of post-surgical pain and swelling in the U.S., SofPulse is also CE-marked in Europe for the promotion of wound health and the palliative treatment of post-surgical pain and edema.

The National Institute on Drug Abuse reports that more than 130 people in the U.S. die each day after overdosing on opioids, while the Centers for Disease Control and Prevention estimates that the opioid crisis costs the nation a cumulative economic burden of more than $78 billion a year (http://nnw.fm/s2Zow).

The global wearable medical devices market is anticipated to grow to $66.8 billion by 2026, a Grandview Research report published in April 2019 suggests (http://nnw.fm/Z72qG). The market is forecast to expand at a CAGR of 26.1 percent over the period, with several factors contributing to the growth. Endonovo’s current portfolio of wearable medical products addresses conditions like liver disease, chronic kidney disease, cardiovascular and peripheral artery disease and ischemic stroke.

For more information, visit the company’s website at www.Endonovo.com

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://nnw.fm/ENDV

About NetworkNewsWire 

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office